| Watchedfields: | changed |
| Verifiedrevid: | 470612121 |
| Iupac Name: | (2S,3aR,7aS)-1-[(2''S'')-2-<nowiki/>{[(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid |
| Width2: | 222 |
| Tradename: | Mavik, others |
| Pregnancy Us: | D |
| Legal Status: | Rx-only |
| Routes Of Administration: | By mouth |
| Protein Bound: | Trandolapril 80% (independent of concentration) Trandolaprilat 65 to 94% (concentration-dependent) |
| Metabolism: | Liver |
| Elimination Half-Life: | 6 hours (trandolapril) 10 hours (trandolaprilat) |
| Excretion: | Fecal and Kidney |
| Iuphar Ligand: | 6453 |
| Cas Number: | 87679-37-6 |
| Atc Prefix: | C09 |
| Atc Suffix: | AA10 |
| Pubchem: | 5484727 |
| Drugbank: | DB00519 |
| Chemspiderid: | 4588590 |
| Unii: | 1T0N3G9CRC |
| Kegg: | D00383 |
| Chebi: | 9649 |
| Chembl: | 1519 |
| C: | 24 |
| H: | 34 |
| N: | 2 |
| O: | 5 |
| Smiles: | O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@H]12)C)CCc3ccccc3 |
| Stdinchi: | 1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1 |
| Stdinchikey: | VXFJYXUZANRPDJ-WTNASJBWSA-N |
| Melting Point: | 119 |
| Melting High: | 123 |
Trandolapril is an ACE inhibitor used to treat high blood pressure. It may also be used to treat other conditions. It is similar in structure to another ramipril but has a cyclohexane group. It is a prodrug that must be metabolized into its active form. It has a longer half-life when compared to other agents in this class.
It was patented in 1981 and approved for medical use in 1993.[1] It is marketed by Abbott Laboratories under the brand name Mavik.
Side effects reported for trandolapril include nausea, vomiting, diarrhea, headache, dry cough, dizziness or lightheadedness when sitting up or standing, hypotension, or fatigue.
Patients also on diuretics may experience an excessive reduction of blood pressure after initiation of therapy with trandolapril. It can reduce potassium loss caused by thiazide diuretics and increase serum potassium when used alone. Therefore, hyperkalemia is a possible risk. Increased serum lithium levels can occur in patients who are also on lithium.
See main article: article.
Trandolapril is teratogenic (US: pregnancy category D) and can cause birth defects and even death of the developing fetus. The highest risk to the fetus is during the second and third trimesters. When pregnancy is detected, trandolapril should be discontinued as soon as possible. Trandolapril should not be administered to nursing mothers.
Combination therapy with paricalcitol and trandolapril has been found to reduce fibrosis in obstructive uropathy.[2]
See main article: article and ACE inhibitor. Trandolapril acts by competitive inhibition of angiotensin converting enzyme (ACE), a key enzyme in the renin–angiotensin system. which plays an important role in regulating blood pressure.